Interview with Joanne Wilson, APRN-NP, DNP: CAR T-Cell Therapy for Solid Tumors

Interview with Joanne Wilson, APRN-NP, DNP: TIL Therapy

Welcome to the CAR T-Cell Therapy Resource Center! Here you’ll find current information, news items, highlights from the literature, case studies, and other resources that focus on CAR T-cell therapies and the advanced practitioner’s role in delivering high-quality care to our patients. If you have any feedback or questions, please contact jadpro-editor@conexiant.com.

Liza Rodriguez, DNP, E-MBA, APRN, AOCNP
APP Manager Hematology/Blood and Marrow Transplant Program
APP Council Chair
Division of Hematologic Malignancies and Cellular Therapeutics
The University of Kansas Cancer Center

Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline

FDA eliminates risk evaluation and mitigation strategies (REMS) for autologous chimeric antigen receptor CAR T-cell immunotherapies

Clinical experience with cranial nerve impairment in the CARTITUDE-1, CARTITUDE-2 cohorts A, B, and C, and CARTITUDE-4 studies of ciltacabtagene autoleucel (cilta-cel)

CAR T-Cell Therapy Resource Center

Interview with Joanne Wilson, APRN-NP, DNP: CAR T-Cell Therapy for Solid Tumors

ASTCT NucleusPlus: Insights on Emerging CAR-T Therapies

CAR T-Cell Therapy for Large B-Cell Lymphoma

CAR T-cell Therapy: Beyond the Storm

Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline

ASTCT 2022 National Fludarabine Shortage for HCT and CAR T-Cell Recipients: Frequently Asked Questions

Seminars in Arthritis and Rheumatism

Advancing autoimmune rheumatic disease treatment: CAR T-cell therapies—evidence, safety, and future directions

Nature Reviews Immunology

In vivo CAR engineering for immunotherapy

Journal for ImmunoTherapy of Cancer

rhIL-7-hyFc, a long-acting interleukin-7, improves efficacy of CAR T-cell therapy in solid tumors

U.S. Food and Drug Administration

FDA eliminates risk evaluation and mitigation strategies (REMS) for autologous chimeric antigen receptor CAR T-cell immunotherapies

Stem Cells Translational Medicine

Anti-viral CD8 central memory veto cells as a new platform for CAR T cell therapy

Journal for ImmunoTherapy of Cancer

Novel PAP-targeted CAR-T therapy enhances antitumor efficacy through CoupledCAR approach

Blood Advances

Inequalities in CAR T-cell therapy access for US patients with relapsed/refractory DLBCL: A SEER-Medicare data analysis

Blood Advances

BCMA-directed CAR T-cell therapy in patients with multiple myeloma and CNS involvement

Transplantation and Cellular Therapy

Clinical experience with cranial nerve impairment in the CARTITUDE-1, CARTITUDE-2 cohorts A, B, and C, and CARTITUDE-4 studies of ciltacabtagene autoleucel (cilta-cel)

Blood Advances

Longitudinal analysis of gut microbiome and metabolome correlates of response and toxicity with idecabtagene vicleucel

Hemophagocytic Lymphohistiocytosis Following CAR T-Cell Therapy in a Patient With Multiple Myeloma

Bloodless Medicine Management of a Patient Receiving CAR T-Cell Therapy

Transverse Myelitis With Paraplegia: An Atypical Manifestation of Neurotoxicity Following CAR T-Cell Therapy

Fast Facts #12: BCMA Targets